DOP2017000018A - [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas - Google Patents

[1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas

Info

Publication number
DOP2017000018A
DOP2017000018A DO2017000018A DO2017000018A DOP2017000018A DO P2017000018 A DOP2017000018 A DO P2017000018A DO 2017000018 A DO2017000018 A DO 2017000018A DO 2017000018 A DO2017000018 A DO 2017000018A DO P2017000018 A DOP2017000018 A DO P2017000018A
Authority
DO
Dominican Republic
Prior art keywords
piridazines
triazolo
treatment
proliferative diseases
formula
Prior art date
Application number
DO2017000018A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Michael James Waring
James Francis Mccabe
Steven Christopher Glossop
Arshed Mahmood
Zoe Ann Cotter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2017000018A publication Critical patent/DOP2017000018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH DRILLING; MINING
    • E21B—EARTH DRILLING, e.g. DEEP DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH DRILLING; MINING
    • E21B—EARTH DRILLING, e.g. DEEP DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I) (FÓRMULA I) O SUS SALES FARMACÉUTICAMENTE ACEPTABLES, DONDE R1, R2 Y N TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS ANTERIORMENTE EN LA PRESENTE EN LA DESCRIPCIÓN; PROCESOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO COMO AGENTES ANTIPROLIFERATIVOS Y/O ANIQUILADORES DE CÉLULAS.
DO2017000018A 2014-07-28 2017-01-18 [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas DOP2017000018A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28

Publications (1)

Publication Number Publication Date
DOP2017000018A true DOP2017000018A (es) 2017-03-15

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000018A DOP2017000018A (es) 2014-07-28 2017-01-18 [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas

Country Status (36)

Country Link
US (5) US9944650B2 (es)
EP (1) EP3174881B1 (es)
JP (1) JP6592503B2 (es)
KR (1) KR20170033427A (es)
CN (1) CN106536524B (es)
AP (1) AP2017009700A0 (es)
AU (1) AU2015295120B2 (es)
BR (1) BR112017001160A2 (es)
CA (2) CA3185741A1 (es)
CL (1) CL2017000223A1 (es)
CO (1) CO2017001918A2 (es)
CY (1) CY1120602T1 (es)
DK (1) DK3174881T3 (es)
DO (1) DOP2017000018A (es)
EA (1) EA032654B9 (es)
ES (1) ES2670444T3 (es)
GT (1) GT201700016A (es)
HR (1) HRP20180788T1 (es)
HU (1) HUE037571T2 (es)
IL (1) IL250104B (es)
LT (1) LT3174881T (es)
MX (1) MX2017001218A (es)
MY (1) MY187251A (es)
NI (1) NI201700006A (es)
NO (2) NO2719005T3 (es)
PE (1) PE20170527A1 (es)
PH (1) PH12017500159B1 (es)
PL (1) PL3174881T3 (es)
PT (1) PT3174881T (es)
RS (1) RS57242B1 (es)
SG (1) SG11201700419SA (es)
SI (1) SI3174881T1 (es)
SV (1) SV2017005368A (es)
TN (1) TN2017000018A1 (es)
WO (1) WO2016016618A1 (es)
ZA (1) ZA201701207B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (es) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
MX2022004555A (es) 2019-10-14 2022-07-21 Astrazeneca Ab Terapia de combinacion para tratar una neoplasia maligna hematologica.
AU2021206140A1 (en) 2020-01-09 2022-08-18 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065664A2 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0821676A2 (pt) * 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
KR20110113755A (ko) * 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
AU2010247190A1 (en) * 2009-05-11 2011-11-10 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
EP2721031B1 (en) * 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (es) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
GT201700016A (es) 2018-12-19
DK3174881T3 (en) 2018-06-06
US20210107905A1 (en) 2021-04-15
PH12017500159A1 (en) 2017-07-10
IL250104B (en) 2018-10-31
AP2017009700A0 (en) 2017-01-31
US20230035133A1 (en) 2023-02-02
MY187251A (en) 2021-09-15
US10407432B2 (en) 2019-09-10
HRP20180788T1 (hr) 2018-06-29
US20180230158A1 (en) 2018-08-16
KR20170033427A (ko) 2017-03-24
NO3174881T3 (es) 2018-08-25
PT3174881T (pt) 2018-05-25
AU2015295120B2 (en) 2018-02-01
US9944650B2 (en) 2018-04-17
AU2015295120A8 (en) 2017-02-09
AU2015295120A1 (en) 2017-02-02
PH12017500159B1 (en) 2017-07-10
IL250104A0 (en) 2017-03-30
TN2017000018A1 (en) 2018-07-04
CA2956421A1 (en) 2016-02-04
CA2956421C (en) 2023-03-14
EP3174881B1 (en) 2018-03-28
CO2017001918A2 (es) 2017-05-10
EP3174881A1 (en) 2017-06-07
EA032654B9 (ru) 2019-07-31
CN106536524B (zh) 2019-11-15
NO2719005T3 (es) 2018-01-20
JP6592503B2 (ja) 2019-10-16
CN106536524A (zh) 2017-03-22
US11407755B2 (en) 2022-08-09
CL2017000223A1 (es) 2017-08-25
NI201700006A (es) 2017-08-25
SG11201700419SA (en) 2017-02-27
SV2017005368A (es) 2017-05-12
JP2017522338A (ja) 2017-08-10
LT3174881T (lt) 2018-06-11
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
US20170210747A1 (en) 2017-07-27
CA3185741A1 (en) 2016-02-04
CY1120602T1 (el) 2019-12-11
ZA201701207B (en) 2018-12-19
EA201790179A1 (ru) 2017-07-31
RS57242B1 (sr) 2018-07-31
PL3174881T3 (pl) 2018-08-31
SI3174881T1 (en) 2018-06-29
EA032654B1 (ru) 2019-06-28
US20200055861A1 (en) 2020-02-20
ES2670444T3 (es) 2018-05-30
HUE037571T2 (hu) 2018-09-28
WO2016016618A1 (en) 2016-02-04
BR112017001160A2 (pt) 2017-11-14
US10766905B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
NI201500167A (es) Compuestos químicos
ECSP19024046A (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2015000170A (es) Compuestos químicos
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
ECSP14013215A (es) Compuestos novedosos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
ECSP18056196A (es) Derivados de indano
CO2017000211A2 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
NI201500172A (es) Composiciones farmacéuticas